Tuesday November 12, 2019
Home Lead Story China Grants ...

China Grants 5G Licenses for Commercial Use: Report

China is set to become the world’s largest 5G market by 2025, with 460 million 5G users, according to a forecast by the Global System for Mobile Communications Association, an industry group

0
//
5G
FILE - Attendees wait in line for a 5G exhibition at the Qualcomm booth during CES 2019 consumer electronics show, at the Las Vegas Convention Center in Las Vegas, Jan. 10, 2019 (Representational image). VOA

China’s Ministry of Industry and Information Technology (MIIT) on Thursday granted 5G licenses for commercial use, marking the beginning of a new era in the country’s telecommunication industry.

The Ministry granted the 5G licenses to the nation’s major three telecom carriers — China Mobile, China Telecom and China Unicom — as well as the state-owned China Broadcasting Network Corp, reports the China Daily.

MIIT Minister Miao Wei said China welcomes foreign companies to actively participate in the construction of the country’s 5G market and share the benefits generated.

The move marks an accelerated push by China to apply 5G. Its previous plan was to commercialize the technology in 2020.

“The 5G licensing will help deepen structural reform in the telecom industry, improve the level of social and economic informatization, and foster several leading companies with global competitiveness,” China Mobile Chairman Yang Jie told the media.

China Mobile has claimed that its 5G services will be available in more than 40 cities by the end of September.

China Unicom noted it will continue to welcome foreign companies to participate in domestic 5G construction.

US clothing brand Gap has apologised for selling T-shirts which it said showed an "incorrect map" of China.
Accurate Map of China. Pixabay

High-speed 5G technology is expected to revolutionize the tech world in the near future, as it will be able to transmit data at least 10 times faster than the 4G system, said the China Daily.

Telecom equipment-maker Huawei Technologies Co said in a statement on Thursday that it is ready to help China accelerate the commercial use of 5G.

Huawei’s global pioneering capabilities to offer 5G solutions can support Chinese telecom carriers to build a sound network, the company said.

The tech giant has invested about $2 billion in total into the research and development of 5G since 2009.

Also Read- Study: Heart, Lungs of Healthy International Travelers Affected Quickly in Polluted Cities

ZTE Corp, another Chinese telecom gear vendor, also said in a statement that its products were ready for commercial use and it will actively participate in the commercial deployment and construction of 5G networks in China, and work closely with industry partners to actively promote the application of 5G.

China is set to become the world’s largest 5G market by 2025, with 460 million 5G users, according to a forecast by the Global System for Mobile Communications Association, an industry group.

The country’s telecom carriers are expected to spend 900 billion to 1.5 trillion yuan ($134 billion to $223 billion) in total on 5G network construction from 2020 to 2025, according to a report from the China Academy of Information and Communications Technology. (IANS)

Next Story

China Okays Sale of First Home-Grown Drug for Treatment of Mild to Moderate Alzheimer’s Disease

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020

0
China, Home, Drug
Oligomannate will provide a new treatment option to fight Alzheimer's disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday. Pixabay

China has approved the first home-grown drug for the treatment of “mild to moderate Alzheimer’s disease (AD) and improving cognitive function”, according to its developers.

The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences.

Oligomannate will provide a new treatment option to fight Alzheimer’s disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday.

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020 to support global regulatory filing of Oligomannate.

China, Home, Drug
The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences. Pixabay

An effective treatment for Alzheimer’s that affects about 48 million people in the world could easily become a big hit globally.

China’s National Medical Products Administration granted Oligomannate fast-track review in November 2018.

Over 800 patients with the diagnosis of mild to moderate Alzhemer’s disease completed the Phase 3 clinical trial conducted in 34 tier-1 hospitals across China.

Results of the 36-week-long study showed that Oligomannate can improve cognitive function in mild-to-moderate Alzheimer’s disease patients as early as week 4 and the benefit was sustained at each follow-up assessment visit.

Also Read- Bengal Focuses on Alternatives after Banning Stubble Burning

Alzheimer’s disease is a progressive brain disorder that impairs memory, affecting the ability of patients to carry out simple tasks. (IANS)